Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-15 02:02 UTC

BIOMED PULSE

Tuesday, July 15, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now surpassed 1,460 confirmed cases and 452 deaths as of July 1, marking the most serious ongoing infectious disease emergency on the planet. The mood is urgent: a PHEIC remains in force, the first-ever treatment trial (PARTNERS) is enrolling patients, and WHO has added the first Bundibugyo diagnostic test to its Emergency Use Listing — cautious progress against a rapidly worsening crisis. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, the DRC reports 1,460 confirmed Bundibugyo virus disease (BVD) cases and 452 confirmed deaths, with sustained transmission and geographic spread persisting into July. [1]
  • WHO declared the BVD outbreak a Public Health Emergency of International Concern (PHEIC) on May 16-17, 2026; the IHR Emergency Committee confirmed it does not yet meet the threshold for pandemic emergency. [4] [5]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, 2026, seeking to raise USD 518 million to support African countries' preparedness and response. [6]
  • WHO issued its first comprehensive clinical management guidelines for all filovirus diseases, covering all Ebola and Marburg virus types, on June 17, 2026, directly in response to the ongoing BVD outbreak. [7]
  • The PARTNERS clinical trial — the first-ever therapeutic trial specifically for Bundibugyo virus disease — opened patient enrollment in DRC on July 2, 2026; the trial aims to identify the first effective BVD treatments. [2]
  • WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing on July 2, 2026; the test detects BDBV genetic material in blood samples for rapid, accurate confirmation. [3]
  • CDC began enhanced Ebola airport screening at Washington-Dulles International Airport on May 21, 2026, subsequently expanding to Atlanta's Hartsfield-Jackson on May 23, 2026. [8] [9]
  • A CDC statement dated July 10, 2026, confirms the agency is actively monitoring and providing updates on the DRC and Uganda outbreak. [10]
  • WHO experts convened on May 28, 2026, to assess candidate treatments and vaccines specifically for Bundibugyo virus, noting no licensed product exists for this strain.

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • WHO's fifth Disease Outbreak News report (July 2, 2026) updates the Andes hantavirus (ANDV) outbreak linked to cruise ship M/V Hondius, first identified May 2, 2026, with additional confirmed cases reported since the previous update of May 28.
  • The original cluster identified at least two laboratory-confirmed Andes hantavirus cases and five suspected cases among 147 passengers and crew as of May 4, 2026, causing severe respiratory illness.
  • CDC's latest hantavirus response transcript is dated June 24, 2026, confirming ongoing U.S. government monitoring of American travelers affected by the M/V Hondius event.

NIPAH VIRUS - INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district: an adult male who developed neurological symptoms on May 30 and was hospitalized June 10.
  • Earlier in 2026, India's IHR Focal Point notified WHO on January 30, 2026, of two healthcare-worker NiV cases in West Bengal (Barasat, North 24 Parganas district), both confirmed at the National Institute.
  • Bangladesh reported one confirmed NiV case in Rajshahi Division in February 2026, with fever and neurological onset on January 21, flagging continued endemicity in the region.

MPOX - RECOMBINANT STRAIN

  • WHO's February 14, 2026, Disease Outbreak News documented two cases of a recombinant mpox virus comprising elements of both clade Ib and clade IIb MPXV — a natural but epidemiologically significant genetic exchange event occurring when two related viruses co-infect a single host.
  • A Phase III randomized, double-blind, placebo-controlled trial (NCT07379580) of BNT166a, an mRNA-based mpox vaccine candidate, opened enrollment in Africa on July 14, 2026, assessing safety, reactogenicity, and immunogenicity after one and two doses.

YELLOW FEVER - GLOBAL

  • WHO's June 24, 2026, Disease Outbreak News reports 79 human yellow fever infections across six countries in Africa and the Americas from January 1 to May 26, 2026, following elevated transmission that persisted from a 2025 surge in the Americas.

WEST NILE VIRUS - UNITED STATES

  • CDC issued an alert on July 1, 2026, warning of an early West Nile season with record case counts as of the Independence Day holiday weekend, urging Americans to use mosquito repellent, eliminate standing water, and wear protective clothing.

MEASLES - BANGLADESH

  • WHO's April 23, 2026, report documents 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of Bangladesh's 64 districts, spanning all eight national divisions.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy's IHR Focal Point notified WHO in late March 2026 of one human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed influenza A(H9N2).

FOOD SAFETY OUTBREAK SIGNALS

  • CDC warned on July 7, 2026, of a recall of frozen blueberries linked to an E. coli outbreak; consumers are advised not to eat recalled products.
  • An active Salmonella outbreak linked to frozen sprouted beans has sickened 11 people across 10 states as of a CDC notice published July 17, 2026 (within the data window).

🧬 LONGEVITY & AGING

NAD+ AND SENESCENT BONE REPAIR

  • Researchers published (Europe PMC, June 27, 2026) a study describing a "senescent metabolism-modulating hierarchical scaffold" that restores NAD+ homeostasis and redox balance in aged bone tissue, potentially offering a biomaterial strategy to accelerate bone repair in elderly patients.
  • NAD+ depletion is a hallmark of cellular senescence; restoring it via engineered scaffolds represents a materials-science approach to geroscience, avoiding systemic drug delivery challenges.

KAEMPFEROL, MORINGA, AND FUNCTIONAL SENESCENCE

  • A Drosophila melanogaster study (Europe PMC, June 25, 2026) found that kaempferol extracted from Moringa oleifera increased lifespan and reduced efavirenz (antiretroviral drug)-induced functional senescence in fruit flies, suggesting a natural flavonoid may counteract drug-accelerated aging.
  • The finding is notable given that the same moringa leaf products are simultaneously linked to multiple ongoing CDC Salmonella outbreaks in the U.S., underscoring the risk-benefit complexity of moringa-based supplements.

TAU, EMERIN, AND NEURODEGENERATION

  • A study published July 7, 2026 (Europe PMC/Nucleus) found that the mechanically sensitive nuclear envelope protein emerin is elevated in response to tau-induced cytoskeletal remodeling in neurons, linking nuclear mechanotransduction to tauopathy — a mechanism relevant to Alzheimer's disease and other age-related dementias.

DELIRIUM AS A BRIDGE FROM INFECTION TO DEMENTIA

  • Two Lancet Healthy Longevity commentaries (Europe PMC, indexed as future-dated but present in the dataset) propose that delirium — a common complication of severe infection in older adults — may be the missing mechanistic link between acute infection and subsequent dementia development.
  • The hypothesis matters clinically because it suggests that preventing or aggressively managing delirium during hospitalization for infections could reduce long-term dementia risk in older patients.

DEMENTIA PREVENTION READINESS

  • A Lancet Healthy Longevity paper by Beeri and Gu argues that the field must prepare for a "dementia prevention era" that accounts for real-world complexity, including socioeconomic variation and multi-morbidity, rather than idealized trial populations.

HYPERTENSION AND FRAILTY IN OLDER ADULTS

  • A letter published July 7, 2026, in Blood Pressure (Europe PMC) highlights evidence from India's Longitudinal Ageing Study linking hypertension to frailty in middle-aged and older adults, reinforcing cardiovascular control as a longevity target in lower-middle-income settings.

CANCER BURDEN PROJECTION

  • WHO's July 8, 2026, report projects that new cancer cases will nearly double by 2050, from an estimated 20.6 million new cases annually today to approximately 35 million, with cancer already claiming over 26,000 lives per day globally.

AMYLOID PET IMAGING IN THE BALTIMORE LONGITUDINAL STUDY OF AGING

  • A ClinicalTrials.gov entry (NCT07099053, updated July 14, 2026) is using amyloid PET imaging within the Baltimore Longitudinal Study of Aging to track how amyloid protein accumulation progresses with age, aiming to distinguish normal from pathological cognitive decline.

VISION AND HEARING IMPAIRMENT AT AGE 50+

  • A Lancet Global Health study (Europe PMC) reports nationally representative data on vision and hearing impairment prevalence among Indigenous and non-Indigenous Australians aged 50 and older, identifying disparities that shorten healthy life expectancy.

💊 NEW CURES & APPROVALS

SARCLISA ESCENA (ISATUXIMAB-IRFC) - SANOFI-AVENTIS U.S. LLC

  • Sanofi-Aventis U.S. LLC received an original FDA Biologics License Application approval (BLA761445) for Sarclisa Escena, active ingredient isatuximab-irfc, an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma.

KEYTRUDA QLEX (PEMBROLIZUMAB + BERAHYALURONIDASE ALFA-PMPH) - MERCK SHARP DOHME

  • Merck Sharp Dohme received a supplemental FDA approval (BLA761467) for Keytruda Qlex, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph — an enzyme that facilitates subcutaneous delivery — expanding the administration options for this PD-1 immune checkpoint inhibitor.

KEYTRUDA (PEMBROLIZUMAB) - MERCK SHARP DOHME

  • Merck Sharp Dohme received an additional supplemental FDA approval (BLA125514) for pembrolizumab (Keytruda), likely a new indication or labeling update for the widely used PD-1 cancer immunotherapy.

PADCEV (ENFORTUMAB VEDOTIN-EJFV) - ASTELLAS

  • Astellas received a supplemental FDA approval (BLA761137) for Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate targeting Nectin-4, used in urothelial cancer treatment.

NINTEDANIB (GENERIC) - GLENMARK PHARMACEUTICALS AND HUMANWELL PURACAP

  • Glenmark Pharmaceuticals Ltd (ANDA212555) and Humanwell Puracap (ANDA218472) each received original FDA approvals for generic nintedanib esylate, a tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease.

RINVOQ LQ (UPADACITINIB) - ABBVIE

  • AbbVie received a supplemental FDA approval (NDA218347) for Rinvoq LQ, a liquid formulation of upadacitinib (JAK1 inhibitor), expanding administration options for its approved indications including rheumatoid arthritis, atopic dermatitis, and Crohn's disease.

ZYOGREEN (INDOCYANINE GREEN INJECTION) - PROVEPHARM SAS

  • Provepharm SAS received an original FDA NDA approval (NDA218579) for Zyogreen, an indocyanine green injection used in medical imaging and fluorescence-guided surgery.

TENOFOVIR ALAFENAMIDE FUMARATE (GENERIC) - LAURUS LABS LTD

  • Laurus Labs Ltd received an original FDA tentative approval (ANDA214030) for generic tenofovir alafenamide fumarate, a nucleotide reverse transcriptase inhibitor used in HIV and hepatitis B treatment.

🧪 CLINICAL TRIALS

PARTNERS TRIAL - BUNDIBUGYO VIRUS DISEASE THERAPEUTICS (DRC)

  • The PARTNERS clinical trial opened patient enrollment in DRC on July 2, 2026, in a major international effort to evaluate the first candidate treatments for Ebola disease caused by Bundibugyo virus, sponsored through WHO coordination. [2]
  • No effective licensed therapeutic currently exists for Bundibugyo virus disease; WHO experts assessed potential vaccines and therapeutics as of May 28, 2026, providing the scientific framework for the trial's candidate selection.

BNT166a MRNA MPOX VACCINE TRIAL - AFRICA (NCT07379580)

  • A randomized, double-blind, placebo-controlled Phase study of BNT166a opened July 14, 2026, evaluating safety, reactogenicity, and immunogenicity of one and two doses of this mRNA-based mpox vaccine candidate in healthy African participants.

ATRASENTAN IN PEDIATRIC IgA NEPHROPATHY (NCT07498335)

  • A Phase III single-arm multicenter trial is evaluating atrasentan, an endothelin A receptor antagonist, in children and adolescents aged 2 to under 18 years with primary immunoglobulin A nephropathy (IgAN), a progressive kidney disease, updated July 14, 2026.

AMYLOID PET IN BALTIMORE LONGITUDINAL STUDY OF AGING (NCT07099053)

  • This observational imaging study is tracking amyloid accumulation via PET scanning in aging volunteers to map the trajectory from normal aging to pathological cognitive decline, with an update recorded July 14, 2026.

NON-PHARMACOLOGICAL INTERVENTION FOR MILD COGNITIVE IMPAIRMENT (NCT07703267)

  • An 8-week community-family mutual support intervention is being tested in adults aged 60 and older with mild cognitive impairment (MCI), comparing the intervention against a control group to assess whether social and cognitive engagement can slow progression to dementia, updated July 14, 2026.

DIGITAL PRECISION REHABILITATION FOR KNEE OSTEOARTHRITIS IN OLDER ADULTS (NCT07695168)

  • This trial integrates multisensory stimulation and digital twin technology into a digital course for older adults with knee osteoarthritis, targeting pain, quadriceps weakness, and balance deficits — common contributors to functional decline in aging, updated July 14, 2026.

SNACKTIVITY INTERVENTION FOR COGNITION IN COPD (NCT07702994)

  • A trial in Hong Kong is testing a culturally adapted Snacktivity program (brief bouts of physical activity) to improve cognitive function and self-care in COPD patients, a population where cognitive decline is common, updated July 14, 2026.

📢 PUBLIC HEALTH

WEST NILE VIRUS EARLY SEASON WARNING

  • CDC data as of July 1, 2026, show weekly emergency room visits for tick bites are higher than usual; separately, West Nile season is running ahead of historical averages with record early case counts — CDC urges insect repellent use and long sleeves outdoors.

WHO CANCER ALARM: CASES PROJECTED TO NEARLY DOUBLE BY 2050

  • WHO's July 8, 2026, report urges urgent global action as new cancer cases are forecast to rise from 20.6 million today to nearly 35 million by 2050, driven by aging populations, tobacco, obesity, and infectious causes; cancer kills more than 26,000 people daily.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026, as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of blindness and affects predominantly impoverished communities.

WHO ON UNSAFE FOOD BURDEN

  • New WHO estimates released June 3-4, 2026, put unsafe food at 866 million illnesses and 1.5 million deaths annually worldwide; children under five face nearly three times the risk of foodborne illness compared with older children and adults.

SALMONELLA OUTBREAK - FROZEN SPROUTED BEANS

  • CDC warns (July 17, 2026) that 11 people in 10 states are sick with the same Salmonella strain linked to frozen sprouted beans; consumers should check recalled products.

E. COLI OUTBREAK - FROZEN BLUEBERRIES

  • CDC posted a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak.

CDC IMMUNIZATION SCHEDULE UPDATES

  • CDC updated its adult and child immunization schedules in October 2025 to shift COVID-19 vaccination to individual-based decision-making, and added standalone varicella vaccination for toddlers as a schedule change.

BIOMED PULSE is an informational briefing only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  4. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  5. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260715-02-v28 · 2026-07-15 02:02 UTC · pulse.uzylab.com

Read next